C. diff Testing: Why a Positive PCR Does Not Always Mean Infection

A positive Clostridioides difficile PCR means one thing only: stool contains bacteria that carry the gene for a toxin. It does not prove those bacteria are making toxin right now, and it does not prove that C. difficile is why the patient has diarrhea. Because a substantial number of healthy people carry toxigenic C. difficile in their gut with no symptoms, a positive nucleic acid amplification test (NAAT) ordered on the wrong patient can turn benign carriage into a diagnosis of disease. The safeguards are two: order the test only when the clinical picture fits, and confirm a positive with a test for free toxin.

Key points#

• A NAAT detects the toxin gene, so it flags both true infection and asymptomatic carriage.
• A toxin assay is less sensitive but more specific for the disease process that antibiotics target.
• Roughly 1 in 13 hospitalized patients already carries toxigenic C. difficile before any illness.
• The most powerful control is upstream: test only unformed stool in patients with genuine, unexplained diarrhea.
• Once a test is positive, do not repeat it to confirm cure; shedding can persist for weeks.

Start with the decision to test, not the test#

Most of the trouble with C. difficile diagnostics happens before a sample reaches the laboratory. No algorithm can rescue a specimen that should never have been collected, so the single highest-value control you have is choosing who and what to test.

The 2017 IDSA/SHEA guideline limits preferred testing to patients with new, unexplained diarrhea, defined as three or more unformed stools within 24 hours. It makes a strong recommendation against testing stool from patients without symptoms, and against retesting within seven days of the same episode. The CDC clinical guidance is equally blunt about specimen quality: laboratories should accept only unformed stool, because a formed sample cannot represent active diarrheal illness in the first place.

Two habits at the bedside cause many false attributions. The first is testing before ruling out other causes, infectious and non-infectious. The second is testing a patient whose loose stool is simply the result of laxatives. The CDC guidance advises stopping laxatives and waiting at least 48 hours before ordering a test, since laxative-driven stool in a colonized patient is a classic trap.

The gene versus the toxin#

C. difficile infection (CDI) is a toxin-mediated disease. Toxins, mainly toxin A and toxin B, injure the lining of the colon. Diagnostics have to answer two different questions, and it helps if you keep them separate.

• Is a toxin-capable organism present? A NAAT answers this. It is highly sensitive and specific for the gene, with sensitivity above 92 percent and specificity above 99 percent, which is precisely why it lights up so readily in people who are merely colonized.
• Is that organism producing toxin during this illness? A toxin enzyme immunoassay answers this. It measures the toxin protein directly. It is far less sensitive, around 75 percent, but fairly specific at about 95 percent, so a positive result points more squarely at the disease that treatment is meant to stop.

A 2024 review in the Journal of Medical Microbiology frames the core limitation cleanly: a positive NAAT indicates only that the toxin gene is present, so by itself it cannot separate active infection from asymptomatic carriage.

That distinction is not academic. The same review reports that mortality attributed to CDI was far lower in patients who were NAAT-positive but toxin-negative than in those who were toxin-positive, on the order of 0.6 percent versus 8.4 percent. In plain terms, a large share of NAAT-positive, toxin-negative patients are carriers whose diarrhea has another explanation.

How multistep algorithms sort carriage from infection#

Because no single assay draws a clean line between colonization and infection, expert bodies recommend chaining tests together. The IDSA/SHEA guideline advises using a stool toxin test as part of a multistep algorithm, such as glutamate dehydrogenase (GDH) plus toxin, or NAAT plus toxin, rather than a NAAT alone, when a laboratory has not agreed in advance on which specimens it will accept. The CDC guidance describes the same two-step design: a high-sensitivity screen (NAAT or GDH) followed by a high-specificity toxin test.

The sequence is deliberate. Step one is built to rule out: a negative sensitive screen makes C. difficile very unlikely, and testing stops there. Step two tries to rule in true infection by finding free toxin. A patient who screens positive but has no detectable toxin lands in an intermediate zone, and you should read that result against the whole clinical picture rather than treating it on reflex. The guideline grades these testing recommendations as weak, precisely because a discordant result still calls for judgment.

Carriage is common, so the denominator drives interpretation#

These rules exist because carriage is not a rare curiosity. A 2025 systematic review and meta-analysis in Gut Pathogens pooled 51 studies covering nearly 40,000 patients and estimated the prevalence of asymptomatic toxigenic C. difficile colonization at about 7.6 percent overall (95% CI 5.7 to 9.7), rising to roughly 8.6 percent among patients tested at hospital admission. Individual cohorts ranged from under 1 percent to more than 50 percent depending on the population.

That baseline reshapes how you should read any positive. When a meaningful fraction of patients already carry the organism, testing people with a low probability of disease (formed stool, minimal symptoms, or an obvious alternative cause) yields positives that mostly mirror the background carriage rate, not the illness in the room. The assay did not malfunction. It answered a question that should not have been asked.

What a misread positive actually costs#

Overdiagnosis here is not a paperwork nuisance. A patient labeled with CDI is typically started on oral vancomycin or fidaxomicin, placed in contact isolation, and counted in facility infection metrics, while the real cause of the diarrhea goes unaddressed. Antibiotics offer no benefit against a disease the patient does not have, and they further disturb the gut community that normally holds C. difficile in check.

The encouraging finding is that diagnostic stewardship moves these numbers. The Journal of Medical Microbiology review describes stewardship, essentially enforcing the test-selection rules above, as cutting C. difficile test orders by about a third. Fewer inappropriate tests produced fewer misleading positives, which in turn meant less unnecessary treatment.